Skip to main content

Table 1 Baseline characteristics of patients

From: Oral beta-lactam step down in bacteremic E. coli urinary tract infections

 

Oral fluoroquinolone step down (n = 130)

Oral beta-lactam step down (n = 77)

p-value

Age, median, years (IQR)

70.5 (56.25–80.75)

71 (54–80)

0.72

Sex

  

0.92

 Female

92 (71)

54 (70)

 

 Male

38 (29)

23 (30)

 

Comorbidities

   

 Diabetes Mellitus

29 (22)

20 (26)

0.55

 Heart Conditions

75 (58)

43 (56)

0.8

 Chronic Kidney Disease

10 (8)

3 (4)

0.28

 Peripheral Vascular Disease

6 (5)

4 (5)

0.85

 Asthma or COPD

14 (11)

7 (9)

0.7

 Liver Cirrhosis

1 (1)

2 (3)

0.56

 Recurrent UTI Risk factors

38 (29)

22 (29)

0.92

 IVDU

5 (4)

0 (0)

0.16

 Hepatitis C

1 (1)

1 (1)

1.0

 HIV

0 (0)

0 (0)

1.0

 Immunocompromised

5 (4)

4 (5)

0.65

Charlson comorbidity index, median (IQR)

1 (0–2)

1 (0–3)

0.96

Catheter associated UTI

6 (5)

4 (5)

0.85

Hospital admission

101 (78)

62 (81)

0.63

ICU admission

9 (7)

5 (6)

0.91

Sepsis

31 (25)

25 (33)

0.2

Septic shock

8 (6)

5 (6)

0.92

Pitt bacteremia score, median (IQR)

0.5 (0–1)

1 (0–1)

0.53

Site of acquisition

  

0.02

 Community-acquired

110 (85)

53 (69)

 

 Community-acquired health-care associated

15 (12)

20 (26)

 

 Hospital-acquired

5 (4)

4 (5)

 

Beta-lactam allergy

15 (12)

7 (9)

0.58

Inadequate empiric treatment

1 (1)

1 (1)

1.0

Stable at oral switch

125 (96)

74 (96)

0.99

Duration of intravenous treatment, median, days (IQR)

5 (3–7)

5 (3–7)

0.20

Duration of oral treatment, median, days (IQR)

7 (7–10)

7 (5.75–10)

0.38

Total treatment duration, median, days (IQR)

14 (12–14)

14 (11–14)

0.91

  1. Data are number (percentage) of patients unless otherwise indicated
  2. Abbreviations: COPD chronic obstructive pulmonary disease, ICU intensive care unit, IVDU intravenous drug use, UTI urinary tract infection;